Tele Launched
Search Menu
Tele Launched
Subscribe

Database and news

Peptides

Research peptides, clinic marketing, access and quality risk coverage

RSS feed

Peptide regulatory status tracker

Where each peptide stands with FDA: its 503A bulks-list status, any FDA-approved product, advisory committee votes and anti-doping status, with the source for every change.

Last verified

Showing 14 of 152 peptides

Search and filter

Peptide Status 503A bulks list FDA-approved product WADA
Amycretin Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Apraglutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Brilacidin Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Cagrilintide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
CagriSema Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Enlicitide FDA-approved Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 Yes — see profile Not listed
Glepaglutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Larazotide acetate Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Mazdutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Pemvidutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Petrelintide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
PN-943 Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Retatrutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed
Survodutide Not FDA-approved Investigational Not nominated Since Sept. 28, 2026, as of Oct. 27, 2026 None Not listed

Source: FDA 503A bulks-list categories, PCAC meeting materials and the WADA Prohibited List

Status labels Not FDA-approved Research use only FDA-approved Investigational Compounded (503A)

What each label means
Not FDA-approved
No FDA approval for any use in humans.
Research use only
Sold as a "research chemical" not for human use. Not FDA-approved; FDA considers such products unapproved new drugs when marketed for human use.
FDA-approved
FDA has approved this drug or biologic as safe and effective for its labeled use.
Investigational
Being studied in clinical trials; not approved by FDA for any use.
Compounded (503A)
Prepared by a state-licensed 503A pharmacy for an individual patient prescription. Compounded drugs are not FDA-approved.

About peptide status

Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.

This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.

If you think you are having a medical emergency, call 911.

Read our full disclaimer

Methodology

Data sources

What we include

  • Peptides that are marketed to consumers through telehealth, compounding pharmacies or “research use only” sellers, or that FDA or its advisory committee has reviewed for the 503A bulks list.
  • The 503A status is the one on FDA’s published lists on the “status as of” date; advisory committee votes are recorded as non-binding recommendations.

How we verify

  • Every status change is dated and linked to the FDA page or meeting materials it comes from.
  • Profiles are reviewed by a clinician or pharmacist on our medical review panel.

Known gaps

  • 503B (outsourcing facility) status is recorded only when FDA has stated it.
  • Advisory committee outcomes are sometimes reported before FDA posts minutes; those records say so.
  • Human trial counts cover registered trials we reviewed, not every published study.

Update frequency: Checked at least weekly and whenever FDA updates its 503A lists or holds a PCAC meeting.

CSV columns (19)

The CSV file is UTF-8 (with a byte-order mark for Excel), comma-separated with CRLF line endings (RFC 4180), one row per record, with these columns in order. Dates are YYYY-MM-DD (U.S. Eastern); list values are separated by semicolons.

profile_url
Peptide profile on this site.
name
Peptide name.
synonyms
Other names, separated by semicolons.
status_503a
503A bulks-list status code.
status_503a_label
503A bulks-list status in plain English.
status_503b
503B (outsourcing facility) status, when known.
fda_approved
true when an FDA-approved drug product contains the peptide.
approved_product
The FDA-approved product, when there is one.
wada
World Anti-Doping Agency status (Prohibited, Not listed, Not assessed).
dea_schedule
DEA controlled-substance schedule, when assessed.
status_labels
Status Label codes shown on the page, separated by semicolons.
last_status_change
Date of the current 503A status (YYYY-MM-DD): the advisory committee vote, FDA listing or bulks-list effective date, by status.
status_source_url
FDA document for the current status.
status_as_of
Date we last verified the status.
human_trial_count
Registered human trials we reviewed on ClinicalTrials.gov.
trial_ids
ClinicalTrials.gov NCT numbers, separated by semicolons.
unii
FDA Unique Ingredient Identifier.
last_reviewed
Date of the last medical/editorial review (YYYY-MM-DD).
last_updated
When this record last changed (ISO 8601).

“Peptide regulatory status tracker.” Tele Launched (dataset). Updated Oct. 27, 2026. Accessed Nov. 7, 2026. https://telelaunched.com/peptides/

Latest in Peptides

  1. Peptides in cash-pay clinics: marketing lines vs medical practice lines